Schistosoma mansoni threatens hundreds of millions of people in >50 countries. Schistosomulae 25 migrate through the lung and adult worms reside adjacent to the intestinal mucosa. None of the 26 candidate vaccines in current development is designed to elicit a mucosal response. We have 27 repurposed an attenuated Salmonella enterica Typhimurium strain (YS1646) to produce such a 28 vaccine targeting Cathepsin B (CatB), a digestive enzyme important for parasite survival. 29 Promoter-Type 3 secretory signal pairs were screened for protein expression in vitro and 30 transfected into YS1646 to generate candidate vaccine strains. Two strains were selected for in 31 vivo evaluation (nirB_SspH1 and SspH1_SspH1). Female C57BL/6 mice were immunized twice, 32 3 weeks apart, using six strategies: i) saline gavage (control), ii) the 'empty' YS1646 vector orally 33 (PO) followed by intramuscular recombinant CatB (20g IM rCatB), iii) two doses of IM rCatB, 34 iv) two PO doses of YS1646-CatB, v) IM rCatB then PO YS1646-CatB and vi) PO YS1646-CatB 35 then IM rCatB. Serum IgG responses to CatB were monitored by ELISA. Three weeks after the 36 second dose, mice were challenged with 150 cercariae and sacrificed 7 weeks later to assess adult 37 worm and egg burden (liver and intestine), granuloma size and egg morphology. CatB-specific 38 IgG antibodies were low/absent in the control and PO only groups but rose substantially in other 39 groups (5898-6766ng/mL). The highest response was in animals that received nirB_SspH1 40 YS1646 PO then IM rCatB. In this group, reductions in worm and intestine/liver egg burden (vs. 41 control) were 93.1% and 79.5%/90.3% respectively (all P<.0001). Granuloma size was reduced in 42 all vaccinated groups (range 32.86-52.83 x10 3 m 2 ) and most significantly in the nirB_SspH1 + 43 CatB IM group (34.74±3.35 x10 3 m 2 vs. 62.22±6.08 x10 3 m 2 : vs. control P<.01). Many eggs in 44 the vaccinated animals had abnormal morphology. Targeting CatB using a multi-modality 45 approach can provide almost complete protection against S. mansoni challenge. 46 Author Summary 47 Schistosomiasis is a parasitic disease that affects over 250 million people worldwide and over 800 48 million are at risk of infection. Of the three main species, Schistosoma mansoni is the most widely 49 distributed and is endemic in the Caribbean, South America, Africa, and the Middle East. It causes 50 a chronic disease with severe negative effects on quality of life. Mass drug administration of 51 praziquantel is the only available course of action due to a current lack of vaccines. However, 52 praziquantel does not protect from reinfection. Therefore, a vaccine would be beneficial as a long-53 term solution to reduce morbidity and transmission of the disease. Our group has repurposed the 54 attenuated YS1646 strain of Salmonella Typhimurium as an oral vaccine vector for the digestive 55 enzyme Cathepsin B of S. mansoni. Oral vaccination followed by an intramuscular dose of 56 recombinant Cathepsin B lead to significant reductions in parasite burden in mice. These animals 57 had the highest titers in serum IgG and intestinal IgA antibodies. This multimodal vaccination 58 approach also elicited both Th1 and Th2 cytokines as seen by the increases in IFNγ and IL-5. 59 Finally, vaccinated mice had reductions in granuloma size along with a higher proportion of 60 morphologically-abnormal eggs. This work demonstrates that a YS1646-based, multimodality, 61 prime-boost immunization schedule can provide nearly complete protection against S. mansoni in 62 a well-established murine model.
Introduction
Suppression of CatB expression using RNA interference (RNAi) has a major impact on parasite 86 growth and fitness [15] . Because the schistosomulae migrate through the lungs and the adult 87 worms reside adjacent to the gut mucosa, we wished to determine if a vaccination strategy that 88 targeted induction of both mucosal and systemic responses to CatB could improve protection.
89
YS1646 is a highly attenuated Salmonella enterica serovar Typhimurium carrying 90 mutations in the msbB (lipopolysaccharide or LPS) and purI (purine biosynthesis pathway) genes 91 that was originally developed as a possible cancer therapeutic [16] . Although its development was 92 halted when it failed to provide benefit in a large phase I trial in subjects with advanced cancer, it 93 was well-tolerated when administered intravenously at doses of up to 3.0x10 8 colony-forming 94 units/m 2 [16] . We are seeking to repurpose YS1646 as a novel vaccination platform and reasoned 95 that a locally-invasive but highly attenuated Salmonella vector might induce both local and 96 systemic responses to CatB. The flagellin protein of S. Typhimurium has been proposed as a 97 general mucosal adjuvant through its action on toll-like receptor (TLR) 5 [17] . Other Salmonella 98 products such as LPS would be expected to further enhance immune responses by triggering TLR4 99 [18, 19] . Indeed, live attenuated Salmonella have multiple potential advantages as vaccine vectors 100 and have been used to express foreign antigens against infectious diseases and cancers [20] [21] [22] .
Aliquots of each transformed strain were stored in LB with 15% glycerol at -80ºC until used in 151 experiments. Western blotting 162 Recombinant YS1646 strains were grown in LB broth with 50 μg/mL ampicillin at 37ºC 163 in a shaking incubator under aerobic or low oxygen (sealed twist-cap tubes) conditions. Bacterial 164 lysates were prepared by centrifugation (9,000xg for 5 min) then boiling the pellet (100ºC x 10 165 min). Proteins from the culture supernatant were precipitated with 10% trichloroacetic acid for 1 166 hour on ice followed by centrifugation (9,000xg for 2 min) and removal of the supernatant. were diluted in DMEM-FBS to give a multiplicity of infection of 100 and centrifuged onto the 187 monolayer (110xg for 10 min) to synchronize the infection. After 1 hour at 37ºC in 5% CO2, plates 188 were washed three times with phosphate buffered saline (PBS: Wisent Bioproducts) and replaced 189 in the incubator with DMEM-FBS containing 50 μg/mL gentamicin (Sigma-Aldrich) to kill any 190 extracellular bacteria and prevent re-infection. After 2 hours, the cells were washed with PBS three 191 times and the gentamicin concentration was lowered to 5 μg/mL. After 24 hours, the cells were 192 harvested, transferred to Eppendorf tubes and centrifuged (400xg for 5 min). Pellets were prepared 193 for western blotting as above. For imaging experiments, RAW 264.7 cells were seeded into 6-well 194 chamber slides at 10 4 cells/well and cultured as above. After 24 hours, the cells were stained with 195 4',6-diamidino-2-phenylindole (DAPI) (Thermo Fisher), fixed with 4% paraformaldehyde in PBS 196 and incubated for 10 min at RT. Images were obtained using a Zeiss LSM780 laser scanning 197 confocal microscope and analyzed using ZEN software (Zeiss, Oberkochen, Germany).
198
Purification of recombinant cathepsin B 199 S. mansoni CatB was cloned and expressed in Pichia pastoris as previously described [12] . 200 Briefly, the yeast cells were cultured at 28ºC with shaking in buffered complex glycerol medium 201 (BMGY) (Fisher Scientific, Ottawa, ON). After two days, cells were pelleted (3,000xg for 5 min) 202 and resuspended in fresh BMMY to induce protein expression. After 3 further days of culture, 203 cells were harvested (3,000xg for 5 min) and supernatants were collected and purified by Ni-NTA Endpoint titers refer to the reciprocal of the highest dilution that gives a reading above the cut-off 266 calculated as previously described [31] .
267
Cytokine production by multiplex ELISA 268 In some experiments, some of the animals were sacrificed 4 weeks after the second 269 vaccination. Spleens were collected and splenocytes were isolated as previously described with University Genome Quebec Innovation Centre) ( Table 1 ). The promoter/T3SS pairs were inserted 303 in-frame with either S. mansoni CatB or eGFP. In monomicrobial culture, CatB expression was 304 effectively driven by the nirB_SspH1, SspH1_SspH1 and SteA_SteA plasmids ( Fig 3A) with the 305 greatest production from the nirB promoter in low oxygen conditions as previously reported [29] . 306 Secreted CatB was detectable in the monomicrobial culture supernatants only with YS1646 307 bearing the SspH1_SspH1 construct ( Fig 3A) . In infected RAW 264.7 cells, all of the constructs 308 produced detectable eGFP by immunofluorescence ( Fig 3B) but only the YS1646 bearing the 309 nirB_SspH1 and SspH1_SspH1 constructs produced CatB detectable by immunoblot ( Fig 3C) .
310
These constructs also led to the greatest eGFP expression in the RAW 264.7 cells and so were 311 selected for in vivo testing. CatB-specific antibody levels even after the second vaccination (395.7 ± 48.9: Fig 4A) . In contrast, 325 all animals that had received at least 1 dose of rCatB IM had significantly higher IgG titers at 6 326 weeks (ie: 3 weeks after the second immunization) ( Fig 4A) . Mice that received nirB_SspH1 PO 327 followed by an IM boost had the highest titers (6766 ± 2128 ng/mL, P<.01 vs. control) but these 328 titers were not significantly different from groups that had received either one (EV→IM) or two 329 doses of rCatB (IM→IM) (5898 ± 1951 ng/mL and 6077 ± 4460 ng/mL respectively, both P<.05 330 vs. control). Antibody titers were generally lower in all groups that received the YS1646 strain 331 bearing the SspH1_SspH1 construct (range 333.5 -3495 ng/mL; P<.05, P<.01, P<.001 vs control: 332 Fig 4B) . Neither IgG subtypes nor intestinal IgA levels were measured in the SspH1_SspH1 333 groups.
334
Control mice had no detectable anti-CatB antibodies and were arbitrarily assigned an 335 IgG1/IgG2c ratio of 1. The PO→PO mice had a ratio of 0.9 ( Fig 4C) . The EV→IM and the 336 PO→IM groups had IgG1/IgG2c ratios of 2.2 and 2.5 respectively while the highest ratios were 337 seen in the IM→IM and IM→PO groups (10.2 and 7.8 respectively).
338
Intestinal IgA levels in the saline, EV→IM, and IM→IM groups were all low (range 37.0 339 -148.0 ng/g of tissue: Fig 4D) . Although the data are variable, groups that received at least one 340 dose of nirB_SspH1 YS1646 PO had increased IgA levels compared to the control group that 341 reached statistical significance in the PO→PO group (402.7 ± 119.7 ng/g) and the PO→ IM group 342 (ie: nirB_SspH1 PO then rCatB IM: 419.6 ± 95.3 ng/g, both P<.01). The IM→PO group also had 343 higher intestinal IgA titers than controls, but this increase did not reach statistical significance 344 (259.8 ± 19.4 ng/g). There was only modest evidence of CatB-specific cytokine production by antigen re-356 stimulated splenocytes immediately prior to challenge (4 weeks after the second dose). There were 357 no significant differences in the levels of IL-2, IL-4, IL-10, IL-12p70, IL-13, IL-17 or TNF-α 358 between vaccinated and control groups (S1 Table) . Compared to the control group, the levels of 359 IL-5 in splenocyte supernatants were significantly higher in mice that received two doses of rCatB 360 (IM→IM) (475.5 ± 98.5 pg/mL, P<.01) and the nirB_SspH1 PO→IM group (364.4 ± 85.2 pg/mL, 361 P<.05) whereas the control group was below the limit of detection at 63.1 pg/mL ( Fig 5A) . Only 362 the PO→IM group had clear evidence of CatB-specific production of IFNγ in response to 363 vaccination (933 ± 237 pg/mL vs. control 216.4 ± 62.5 pg/mL, P<.05) (Fig 5B) . respectively. (Fig 6A) . 380 Overall, the reductions in hepatic and intestinal egg burden followed a similar pattern to 381 the vaccine-induced changes in worm numbers. The hepatic and intestinal egg burden in the saline-382 vaccinated control mice ranged from 1,994 -13,224 eggs/g and 6,548 -24,401 eggs/g 383 respectively. Reductions in hepatic eggs in the EV→IM and IM→IM groups were modest at 18.9% 384 and 32.7% respectively. Reductions in intestinal eggs followed a similar trend: 15.4% and 43.6% 385 respectively. In the groups that received the SspH1_SspH1 YS1646 strain, PO→PO immunization 386 did not perform any better with 11.6% and 18.3% reductions in hepatic and intestinal egg numbers 387 respectively. Somewhat greater reductions in hepatic and intestinal egg burden were seen in the 388 PO→IM (51.3% and 60.9% respectively) and IM→PO groups (17.7% and 29.8% respectively).
389
These apparent differences in egg burden between the two multi-modality groups did not parallel 390 the reductions in worm numbers or the systemic anti-CatB IgG levels. Groups that received the 391 nirB_SspH1 strain had more consistent and greater reductions in egg burden: the PO→PO group 392 had 73.6% and 69.2% reductions in hepatic and intestinal egg numbers respectively (both P<.001).
393
The greatest impact on hepatic and intestinal egg burden was seen in the nirB_SspH1 multi-394 modality groups: 90.3% (P<.0001) and 79.5% (P<.0001) respectively in the PO→IM group and 395 79.4% (P<.001) and 75.9% (P<.0001) respectively in the IM→PO group (Figs 6B and 6C) . Hepatic granulomas were large and well-formed in the PBS-treated control mice (62.2 ± 403 6.1 x10 3 m 2 ) and essentially all of the eggs in these granulomas had a normal appearance. The 404 EV→IM and IM→IM groups had slightly smaller granulomas (52.0 ± 6.9 x10 3 m 2 and 52.8 ± 405 10.4 x10 3 m 2 respectively) with modest numbers of abnormal-appearing eggs (ie: loss of internal 406 structure, crenellated edge) (Table 2) but these differences did not reach statistical significance.
407
Groups that received the SspH1_SspH1 strain had granuloma sizes ranging from 47.3-55.0 x10 3 408 m 2 with 30.5% of the eggs appearing abnormal in the PO→IM and 28.6% IM→PO groups (both 409 P<.05). In the groups that received the nirB_SspH1 strain, both the purely oral (PO→PO) and 410 multi-modality strategies (PO→IM and IM→PO) resulted in even smaller granulomas (32.9 ± 2.0 411 m 2 , 34.7 ± 3.4 x10 3 m 2 and 39.2 ± 3.7 x10 3 m 2 : P<.01, P<.01 and P<.05 respectively) . The 412 large majority of the eggs in these granulomas had disrupted morphology (75.9 ± 7.6%, 79.4 ± 413 4.2% and 71.9 ± 6.0% respectively: all P<.0001). Overall, the greatest and most consistent 414 reductions in both adult worm numbers and egg burdens in hepatic and intestinal tissues were seen 415 in the animals that received oral dosing with the YS1646 bearing the nirB_SspH1_CatB construct 416 followed 3 weeks later by IM rCatB. 32.9 ± 2.0 ** 75.9 ± 7.6 **** nirB_SspH1 + rCatB 34.7 ± 3.4 ** 79.4 ± 4.2 **** rCatB + nirB_SspH1 39.2 ± 3.7 * 71.9 ± 6.0 **** Liver granuloma area (x10 3 m 2 ) and egg morphology (ie: loss of internal structures, shrinkage, Our group has previously described the protective efficacy of CatB-based vaccines delivered 436 IM with adjuvants. Using CpG dinucleotides to promote a Th1-type response, vaccination resulted 437 in a 59% reduction in worm burden after challenge with 56% and 54% decreases in hepatic and 438 intestinal egg burden respectively compared to adjuvant-alone control animals [12] . Parasitologic 439 outcomes were slightly better in the same challenge model when the oil-in-water adjuvant 440 Montanide ISA 720 VG was used to improve the antibody response: 56-62% reductions in worm 441 numbers and the egg burden in tissues [13] . These results were well above the 40% threshold 442 suggested by the TDR/WHO and provided proof-of-concept for CatB as a promising target 443 antigen. Based on this success, we expanded our vaccine discovery program to explore alternate 444 strategies and potentially more powerful delivery systems. The availability of the highly attenuated 445 Salmonella enterica Typhimurium strain YS1646 that had been used in a phase 1 clinical cancer 446 trial at doses up to 3x10 8 IV was attractive for many reasons. Although S. enterica species replicate 447 in a membrane-bound host cell compartment or vacuole [36] , foreign protein antigens can be 448 efficiently exported from the vacuole into the cytoplasm using the organism's T3SS. Like all 449 Salmonella enterica species, YS1646 has two distinct T3SS located in Salmonella pathogenicity 450 islands 1 and 2 (SPI-I and SPI-II) [37] that are active at different phases of infection [38] . The SPI-451 I T3SS translocates proteins upon first contact of the bacterium with epithelium cells through to 452 the stage of early cell invasion while SPI-II expression is induced once the bacterium has been 453 phagocytosed [39]. These T3SS have been used by many groups to deliver heterologous antigens 454 in Salmonella-based vaccine development programs [22, 40] .
417

455
In this study, we report the protective efficacy of CatB delivered by the attenuated strain 'prime-pull' strategies to optimize mucosal responses (ie: 'prime' in the periphery then 'pull' to 492 the target mucosa) [50] , it is interesting that both the Chen group and our own findings suggest 493 that PO→IM dosing may be the optimal strategy. In the S. japonicum model targeting the long 494 hydrophobic domain of the surface exposed membrane protein Sj23LHD and a host-parasite 495 interface enzyme (glutathione S-transferase or GST), the PO→IM vaccination schedule led to 496 important reductions in both worm numbers (51.4%) and liver egg burden (62.6%) [29] .
497
In addition to the substantial overall reductions in worm numbers and egg burden in our 498 animals that received multimodality vaccination, there were additional suggestions of benefit in 499 terms of both hepatic granuloma size and possible reduced egg fitness ( Table 2 ). The size of liver 500 granulomas is determined largely by a Th2-deviated immune response driven by soluble egg 501 antigens (SEA) [51] . Prior work with CatB vaccination suggests that IM delivery of this antigen 502 alone tends to elicit a Th2-biased response that can be shifted towards a more balanced Th1/Th2 503 response by CpG or Montanide [12, 13, 52] . The reduction in the anti-CatB IgG1/IgG2c ratio 504 between the IM→IM only and multimodality groups (IM→PO, PO→IM) supports the possibility 505 that combined recombinant CatB with YS1646 bearing CatB can induce a more 'balanced' pattern 506 of immunity to this antigen and, at least in a limited sense, that the YS1646 is acting as a Th1-type 507 adjuvant ( Fig 4C) . Although no adjuvants were included in the current study, the YS1646 vector 508 might reasonably be considered 'auto-adjuvanted' by the presence of LPS, even in an attenuated 509 form, and flagellin which can act as TLR-4 and TLR-5 agonists respectively. It was still surprising 510 however, that the average hepatic granuloma size was significantly smaller in our multi-modality 511 groups than in the IM alone group since no CatB is produced by the eggs (Table 2) . This 512 observation raises the interesting possibility that the YS1646-based vaccination protocol may be 513 able to influence the overall pattern of immunity to S. mansoni and/or reduce the fitness of the 514 eggs produced (as suggested by the abnormal egg morphology observed). Such effects could 515 significantly extend the value of the combined PO→IM vaccination strategy, i.e.: more durable 516 impact, reduced transmission, etc. Furthermore, prior work with IM vaccination with CatB alone 517 revealed a Th2-type pattern of cytokine response in splenocytes (eg: IL-4, IL-5, and IL-13) [52] .
518
In the current work we observed increases in both IFNγ and IL-5 in the multimodality PO→IM 519 group (Fig 5) , suggesting that YS1646 vaccination can induce more balanced Th1-Th2 immune 520 response. Finally, this study did not consider the possible role of other immune mechanisms in 521 controlling S. mansoni infection after YS1646 infection and we have previously shown that CD4 + 522 T cells and anti-schistosomula antibody-dependent cellular cytotoxicity (ADCC) contribute to 523 protection after CatB immunization (± adjuvants) [53] . Studies are underway to examine these 524 possibilities with the multi-modality YS1646-based vaccination protocols. It is also intriguing that 525 the apparent efficacy of either one or two IM doses of rCatB differed considerably between the 526 EV→IM and IM→IM groups with the latter schedule eliciting significantly greater protection for 527 all parasitologic outcomes despite the fact that these groups had similar levels of serum anti-CatB 528 IgG at the time of challenge (Fig 4) . Future studies will address whether or not there are qualitative 529 differences in the antibodies induced (ie: avidity, isotype, competence to mediate ADCC) and/or 530 differences in other immune effectors (ie: CD4 + or CD8 + T cells).
531
Although the findings presented herein are promising, this work has several limitations. First, 532 immune protection is likely to be relatively narrow when only a single schistosome antigen is 533 targeted. In the long term, this limitation could be easily overcome by adding one or more of the 534 many S. mansoni target antigens that have shown promise in pre-clinical and/or clinical 535 development (eg: GST, Sm23, Sm-p80, etc) to generate a 'cocktail' vaccine. In this context, an 536 attenuated Salmonella vector like YS1646 might be ideal because of its high 'carrying capacity' 537 for foreign genes [54] . Second, our current findings are based on plasmid-mediated expression and 538 pQE30 contains a mobile ampicillin resistance gene that would obviously be inappropriate for use 539 in humans [55] . Although chromosomal integration of our nirB_SspH1_CatB gene is an obvious 540 mitigation strategy, expression of the CatB antigen from a single or even multiple copies of an 541 integrated gene would likely be lower than plasmid-driven expression. Finally, the degree to which 542 a vaccination schedule based on the YS1646 vector would be accepted by regulators is currently 
